News

2022 Senior Satisfaction Survey with Medicare Part D from Medicare Today

Each year Medicare Today conducts a nationwide survey to find out how seniors feel about their coverage of prescription medications through Medicare. This year, the Senior Satisfaction Survey found that beneficiaries’ satisfaction with the coverage Part D provides has actually increased over the year, speaking to the program’s consistent success among seniors.

ABC4 News story: Co-pay assistance protection bill could save vulnerable families thousands

UTAH (ABC4) – The minute Penny Hepworth was diagnosed with cystic fibrosis, her mother Jennifer became an expert on the condition and health insurance. 

“It’s not unusual for a parent with a child with cystic fibrosis to be on the phone with the insurance at the beginning of the year, an average of 30 hours a month,” said Jennifer Hepworth. 

After years of figuring out what worked best for her daughter, Jennifer came across a new problem, co-pay accumulator programs. 

“It’s a despicable program,” said Hepworth. 

Read the full story at ABC4 News.

Desert News Op-ed: Lawmakers should do this to help families dealing with cystic fibrosis

With a simple, straightforward reform, the Utah Legislature could end copay accumulator programs that add to financial burdens.

Paying for innovative, effective, lifesaving medications for families like ours who have a child living with a chronic and deadly disease is a huge financial burden that is exacerbated by insurance company policies that refuse to recognize essential prescription assistance Utah families receive.

Read the full opinion piece at Desert News.

Patient organizations in letter to Utah Delegation urge opposition to H.R. 3

Letter excerpt:

Dear Members of the Utah Congressional Delegation,

On behalf of the undersigned organizations and the many constituents we represent, we would like to express our concern with the reintroduction of H.R. 3, The Lower Drug Costs Now Act, and urge you to oppose this legislation. H.R. 3 would have a devastating impact on patient access to critical medicines and would discourage the growth of and even penalize biopharmaceutical companies that are developing life-changing treatments and cures for patients.

Full letter below.

Utah-Congressional-Delegation-Ltr.-HR3-5.25.21